Joseph Haas

Joseph Haas

Senior Writer

Washington, DC

Joe has covered a wide range of biopharmaceutical stories since 2007 and contributes to Scrip, In Vivo, Pink Sheet and related Citeline publications. His specialties include business development, commercial strategies and liver and infectious diseases.

Latest from Joseph Haas

Altimmune Outlines Pemvidutide Plans In MASH And Beyond

The company sees potential for the GLP-1/glucagon receptor dual agonist in MASH as well as alcohol-related liver disease as hopes to move pemvidutide into Phase III in obesity with a partner.

Asia Deal Watch: Daiichi Sankyo Teams With Nosis On Extrahepatic RNA Therapies

Plus deals involving Hyundai/Pharma/Avelos, Yuhan/Boehringer Ingelheim, SciClone/Eisai, Viatris/Nxera/Idorsia, Nxera/Holling and Takeda/BridGene.

Endo And Mallinckrodt Plan To Merge - And Spin Off Generics Business

Both vexed by bankruptcies and opioid litigation, Endo and Mallinckrodt will merge in a deal valued at $6.7bn. The new company will spin out its generics and sterile injectable business.

Like Seeks Out Like: Endo And Mallinckrodt Plan To Merge

Both vexed by bankruptcies and opioid litigation, Endo and Mallinckrodt will merge in a deal valued at $6.7bn. The new company will spin out its generics and sterile injectable business.

Ionis Gets Tryngolza Launch Cash From Ono Via Sapablursen License

Ono agreed to pay $280m up front for global rights to Ionis’s Phase II polycythemia vera candidate, which analysts say was de-risked by recent data reported for other PV drugs.

Scrip M&A Podcast: Looking At M&A Activity As Q1 Nears A Close

Scrip senior writer Joseph Haas discusses recent industry merger-and-acquisition activity with attorneys Jessica Bisignano and Gabrielle Witt of Hogan Lovells.